Loading menu...
Prostate cancer is the second leading cause of cancer deaths among US men  Over 200,000 new patients are diagnosed with prostate cancer every year in the US alone  About 35,000 of these men have advanced metatstatic prostate tumor for whom there is no cure 

Prostate Cancer
Colby Mission
Drug Pipeline

Pipeline

Pipeline

Colby Pharmaceutical Company is developing two lead drugs, CPC-100 and CPC-200, and two pipeline drugs, CPC-300 and CPC-410.  These four are all small molecule Oxidative Stress Modulator (OSM) drugs each with different targets for patients at the four different stages of recurrent prostate cancer.

Colby Drug Development Projected Timelines

Drug Development Pipeline

 

Colby’s OSM drugs act directly at the cellular metabolic sources of oxygen free radicals in prostate and certain other human cells and inhibit tissue oxidative damage, inflammation, tumor progression, angiogenesis and metastasis. The diseased and cancerous prostate epithelial cells can be therapeutically treated with OSM drugs with little or no significant effect on normal prostate cells.